Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer

Multicenter Cohort Study of Chemo-radiotherapy After Endoscopic Submucosal Dissection for High-risk Early-stage Esophageal Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06385717

Acronym

ESCORT

Enrollment

120

Registered

2024-04-26

Start date

2024-05-01

Completion date

2029-01-31

Last updated

2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagus Cancer

Keywords

esophagus cancer; radio-chemotherapy; ESD

Brief summary

This multicenter, prospective observational cohort study has the potential to optimize individualized chemoradiotherapy regimen for early-stage esophageal cancer patients who have received endoscopic submucosal dissection.

Detailed description

Our study can further improve the local-regional lymph nodes control rate and alleviate the toxicity of chemoradiotherapy.

Interventions

RADIATIONchemo-radiation

different Chemo-radiotherapy regimen

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 1\. Esophageal cancer patients who are pathologically confirmed as pT1a-MM stage or pT1b stage after endoscopic submucosal dissection； 2. No definite contraindications for chemo-radiotherapy； 3. Informed consent has been signed； 4. Refused surgery after endoscopic submucosal dissection.

Exclusion criteria

* 1\. Severe heart, brain, lung disease or renal dysfunction; 2. Previous history of other malignancies; 3. Prior radiation or chemotherapy 4. Researchers consider it inappropriate to participate in this experiment

Design outcomes

Primary

Measure	Time frame	Description
Incidence of toxic events	2026.2	esophageal stenosis, radiation pneumonitis, etc

Secondary

Measure	Time frame	Description
3-year overall survival	2029.1	the time from randomization until death from any cause
3-year local-regional recurrence free survival	2029.1	the time from randomization until local-regional recurrence

Countries

China

Contacts

Primary ContactJing Xu, MD

jing_xu@zju.edu.cn0086-0571-87783521

Backup ContactQichun Wei, PHD

qichun_wei@zju.edu.cn0086-0571-87783521

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026